Arecor Therapeutics plc
AREC.L
London Stock Exchange63.50
GBp
- -
- -
Arecor Therapeutics plc
AREC.L
(London Stock Exchange)
Recent
price
63.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Arecor Therapeutics plc Arecor Therapeutics plc, a clinical-stage biopharmaceutical company listed on the London Stock Exchange, develops enhanced formulations of existing therapeutic medicines using its proprietary Arestat platform to improve stability, performance, and patient outcomes in areas including diabetes, obesity, and hospital care. The company offers an internal proprietary portfolio comprising AT278, a concentrated rapid-acting insulin for Type 2 diabetes; AT247, an ultra-rapid acting insulin for artificial pancreas systems; and Oral GLP-1, an oral formulation for diabetes and obesity treatments; alongside partnered programs such as ready-to-administer hospital products licensed to Hikma Pharmaceuticals, biosimilars like AT220, and other peptide therapies reformulated for superior properties including extended shelf-life, room-temperature stability, and high-concentration delivery. Founded in 2007 and headquartered at Chesterford Research Park in Little Chesterford, United Kingdom, Arecor Therapeutics plc operates globally, partnering with pharmaceutical, biotechnology, and medtech firms to co-develop differentiated biosimilars, vaccines, monoclonal antibodies, and ready-to-use formats targeting patients with unmet needs in endocrinology and acute care settings. Recent developments include a September 2025 co-development agreement with Sequel Med Tech for integration of AT278 with its automated insulin delivery system; a royalty financing deal with Ligand Pharmaceuticals yielding up to $11 million in non-dilutive funding from AT220 and AT292 royalties to extend cash runway into mid-2027; enhanced intellectual property filings in November 2025 for AT278 and oral delivery technology; executive and non-executive board changes in September 2025; and a decision in January 2025 to cease operations of subsidiary Tetris Pharma.